Clinical trials data
Digit Span Test in cancer trials: 107 registered studies
Every registered cancer study on ClinicalTrials.gov that names the Digit Span Test in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cancer studies name it in an outcome measure
- 107
- Name it in a primary outcome, 38%
- 41 of 107
Tests named in the same studies
- 1
Verbal Learning66 studies, 23 as a primary outcome
- 2
Verbal Fluency62 studies, 21 as a primary outcome
- 3
Trail Making Test52 studies, 19 as a primary outcome
- 4
Symbol Coding27 studies, 14 as a primary outcome
- 5
Stroop Color-Word Test24 studies, 12 as a primary outcome
- 6
Category Fluency15 studies, 4 as a primary outcome
- 7
Continuous Performance Test9 studies, 4 as a primary outcome
- 8
Short Story Recall8 studies, 3 as a primary outcome
- 9
Symbol Scan Task8 studies, 3 as a primary outcome
- 10
Paced Visual Serial Addition Test5 studies, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 2 | 0 |
| 2008 | 0 | 0 |
| 2009 | 2 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 2 | 2 |
| 2013 | 3 | 1 |
| 2014 | 5 | 2 |
| 2015 | 6 | 2 |
| 2016 | 5 | 0 |
| 2017 | 8 | 1 |
| 2018 | 3 | 1 |
| 2019 | 5 | 1 |
| 2020 | 6 | 4 |
| 2021 | 7 | 3 |
| 2022 | 6 | 1 |
| 2023 | 9 | 3 |
| 2024 | 12 | 7 |
| 2025 | 6 | 1 |
| 2026 | 13 | 6 |
Phases and study sizes
By phase
- Early phase 12 studies, 1 as a primary outcome
- Phase 12 studies, 0 as a primary outcome
- Phase 210 studies, 3 as a primary outcome
- Phase 39 studies, 2 as a primary outcome
- Not applicable59 studies, 23 as a primary outcome
- Observational25 studies, 12 as a primary outcome
Participants per study
- Phase 284 median, 56 to 155
- Not applicable70 median, 43 to 110
- Observational65 median, 35 to 120
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 10 | 84 | 56 to 155 |
| Not applicable | 57 | 70 | 43 to 110 |
| Observational | 25 | 65 | 35 to 120 |
When cancer trials measure it
Latest time point of each outcome
- Within a day8 outcomes, 3 as a primary outcome
- Up to 4 weeks8 outcomes, 4 as a primary outcome
- 1 to 3 months18 outcomes, 9 as a primary outcome
- 3 to 6 months26 outcomes, 7 as a primary outcome
- 6 to 12 months25 outcomes, 8 as a primary outcome
- 1 to 2 years8 outcomes, 3 as a primary outcome
- Over 2 years11 outcomes, 4 as a primary outcome
- No duration given3 outcomes, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
104 of the 107 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting28 studies, 11 as a primary outcome
- Not yet recruiting7 studies, 3 as a primary outcome
- Active, not recruiting11 studies, 3 as a primary outcome
- Completed35 studies, 13 as a primary outcome
- Stopped early11 studies, 5 as a primary outcome
- Status unknown15 studies, 6 as a primary outcome
What they test
- Behavioral32 studies, 13 as a primary outcome
- Drug22 studies, 8 as a primary outcome
- Device11 studies, 4 as a primary outcome
- Procedure6 studies, 1 as a primary outcome
- Diagnostic test4 studies, 1 as a primary outcome
- Biological1 studies, 0 as a primary outcome
- Radiation12 studies, 3 as a primary outcome
- Other33 studies, 12 as a primary outcome
- None given10 studies, 5 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States42 studies, 20 as a primary outcome
- Canada9 studies, 1 as a primary outcome
- Denmark8 studies, 2 as a primary outcome
- Netherlands7 studies, 2 as a primary outcome
- Italy6 studies, 4 as a primary outcome
- Spain6 studies, 1 as a primary outcome
- Australia4 studies, 1 as a primary outcome
- United Kingdom4 studies, 0 as a primary outcome
- Germany3 studies, 1 as a primary outcome
- Hong Kong3 studies, 2 as a primary outcome
- Norway3 studies, 0 as a primary outcome
- Belgium2 studies, 0 as a primary outcome
25 countries in all. A study with sites in several counts in each; 3 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cancer studies that name the Digit Span Test: 20 of 35, 57%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cancer studies that name the Digit Span Test | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 3, 9% | 776, 10% |
| Results on ClinicalTrials.gov only | 9, 26% | 1,139, 14% |
| A results paper only | 8, 23% | 1,711, 22% |
| Neither | 15, 43% | 4,327, 54% |
The 107 studies
107 studies match. 41 name the Digit Span Test in a primary outcome. Median size 67 participants. Median time to the primary outcome: 6 months.
Loading 107 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 2 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 2 | 0 |
| 2008 | 0 | 0 |
| 2009 | 2 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 2 | 2 |
| 2013 | 3 | 1 |
| 2014 | 5 | 2 |
| 2015 | 6 | 2 |
| 2016 | 5 | 0 |
| 2017 | 8 | 1 |
| 2018 | 3 | 1 |
| 2019 | 5 | 1 |
| 2020 | 6 | 4 |
| 2021 | 7 | 3 |
| 2022 | 6 | 1 |
| 2023 | 9 | 3 |
| 2024 | 12 | 7 |
| 2025 | 6 | 1 |
| 2026 | 13 | 6 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 2, NIH 1, other 104. Interventional 82, observational 25.
As a primary outcomeSecondary or other outcomeThe Digit Span Test
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07908147 | Start2027 | PhaseEarly phase 1 | ConditionsCancer | Participants12 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07769099 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants236 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07755839 | Start2026 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Cancer, Anxiety, PTSD and OCD | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07740317 | Start2026 | PhaseObservational | ConditionsCancer | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07729969 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants110 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07716306 | Start2027 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07710131 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants36 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07652476 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07633626 | Start2026 | PhaseObservational | ConditionsDepression and bipolar disorder, Cancer | Participants24 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07586722 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants32 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07553481 | Start2026 | PhaseObservational | ConditionsCancer | Participants172 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07448103 | Start2026 | PhaseNot applicable | ConditionsBrain injury and concussion, Cancer | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07147621 | Start2026 | PhaseObservational | ConditionsCancer | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07083518 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07061626 | Start2026 | PhasePhase 1 | ConditionsCancer | Participants56 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07046936 | Start2026 | PhaseObservational | ConditionsCancer | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07021339 | Start2024 | PhasePhase 3 | ConditionsCancer | Participants178 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06905587 | Start2025 | PhasePhase 3 | ConditionsCancer, Pain and fatigue | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06878469 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06727773 | Start2025 | PhasePhase 2 | ConditionsCancer | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06727370 | Start2024 | PhaseObservational | ConditionsCancer, Lung disease | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06693102 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06606535 | Start2024 | PhaseObservational | ConditionsCancer | Participants60 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06589544 | Start2024 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Cancer | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06584110 | Start2024 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Cancer | Participants236 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many cancer trials use the Digit Span Test?
107 registered cancer studies on ClinicalTrials.gov name it in an outcome measure, 41 of them in a primary outcome: 14% of the condition's 760 studies with a cognitive outcome, against 10% of all of them. It is the 4th most named test in cancer trials.
Which tests do cancer trials use with the Digit Span Test?
Verbal Learning (66 studies), Verbal Fluency (62 studies) and the Trail Making Test (52 studies).
How many participants do phase 2 cancer trials that use the Digit Span Test enroll?
Half of the phase 2 studies that name it enroll 84 participants or fewer, and the middle half enroll 56 to 155. 10 of them give a size.
When do cancer trials measure the Digit Span Test?
Half of the primary outcomes that name the Digit Span Test are measured within 6 months of the start, and the middle half from 12 weeks to 12 months. 38 primary outcomes give a duration.
How many completed cancer trials that use the Digit Span Test have reported results?
20 of the 35 completed studies that name it, 57%, have reported results: 12 posted them on ClinicalTrials.gov, 11 have a results paper linked to the registry record, and 3 did both. The other 15 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run the Digit Span Test in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.